Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083063 | 0.89 | NPC1 (0.57) | NPC1KDM4EPKMRAB9AALDH1A1 | |
| SCHEMBL14083722 | 0.86 | NPC1 (0.57) | NPC1KDM4EPKMRAB9AALDH1A1 | |
| SCHEMBL14083851 | 0.85 | KDM4E (0.55) | NPC1KDM4EPKMRAB9AALDH1A1 | |
| SCHEMBL14083470 | 0.82 | TRPV1 (0.77) | KDM4ETRPV1MEN1KMT2ATRPV4 | |
| SCHEMBL14082841 | 0.82 | TRPV1 (0.77) | TRPV1KMT2ATRPV4MAPK1 | |
| SCHEMBL14083467 | 0.81 | TRPV1 (0.75) | NPC1RAB9ALMNATRPV1TRPV4 | |
| SCHEMBL14083879 | 0.80 | TRPV1 (0.78) | TRPV1TRPV4 | |
| SCHEMBL3872091 | 0.80 | TRPV1 (0.78) | NPC1RAB9ATRPV1TRPV4 | |
| SCHEMBL14083469 | 0.80 | TRPV1 (0.78) | TRPV1TRPV4 | |
| SCHEMBL14083471 | 0.80 | TRPV1 (0.67) | NPC1KDM4ERAB9ALMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | NPC1 1061/4885KDM4E 4231/4885PKM 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.